Investigating COVID-19 burden in people with neurofibromatosis type 1
poster
posted on 2021-07-08, 19:21 authored by Jineta Banerjee, Robert AllawayRobert Allaway, Jan Friedman, Laura J Klesse, Kaleb Yohay, Justin T. Jordan, Scott R. Plotkin, Jaishri O. Blakeley- COVID-19 can have significant consequences for people with some pre-existing conditions; it is not clear whether COVID-19 has similar consequences for people with neurofibromatosis (NF)
- We explored electronic healthcare record (EHR) data to learn more about COVID-19 in people with neurofibromatosis type 1 (we did not have enough data to study NF2 or schwannomatosis)
- We explored electronic healthcare record (EHR) data to learn more about COVID-19 in people with neurofibromatosis type 1 (we did not have enough data to study NF2 or schwannomatosis)
- Our results suggest that people with NF1 do not have a greater risk for COVID-19 positivity or severe outcomes than the general age-matched population
The analyses described in this presentation were conducted with data or tools accessed through the NCATS N3C Data Enclave (https://covid.cd2h.org) and N3C Attribution & Publication Policy v 1.2-2020-08-25b supported by NCATS U24 TR002306 and the Neurofibromatosis Therapeutic Acceleration Program. This research was possible because of the patients whose information is included within the data and the organizations (https://ncats.nih.gov/n3c/resources/data-contribution/data-transfer-agreement-signatories) and scientists who have contributed to the on-going development of this community resource [https://doi.org/10.1093/jamia/ocaa196]
